{"analyses":[{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.858","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.71","upperLimit":"36.14","value":"30.7"},{"groupId":"OG001","lowerLimit":"23.14","upperLimit":"31.86","value":"27.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"332"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of final analysis were censored at the date of the last follow up. The final analysis for OS was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. OS analysis is reported here for all randomized participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"OG000","title":"Vorinostat"},{"description":"Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All participants randomized to a study arm.","reportingStatus":"POSTED","timeFrame":"Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Weeks"}